HW211026
Phase 2Small molecule
HW211026 is one of 25 small molecule programs targeting Actinic Keratosis. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
95 competitors in Actinic Keratosis
#DrugCompanyPhaseTrials
1Voltaren
CCerimon Pharmaceuticals
Phase 3
Treatment
GSKPhase 3
Ingenol Metabute
LEO PharmaPhase 3
Levulan
BBiomed Industries, Inc.
Phase 2
Generic Ingenol Mebutate
AActavis Inc.
Phase 3
Accutane
CConrado Roberto Hoffmann Filho
Phase 2
Lanoxin
AAdvanz Pharma
Phase 2
Ornidyl
UUSWM, LLC (dba US WorldMeds)
Phase 2
Kenalog
BBassett Healthcare
Phase 2
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Actinic Keratosis2 trials
A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.
Recruiting·HHubei Bio-Pharmaceutical Industrial Technological Institute Inc.·Phase 1·NCT07318675·40 enrolled
A Multicenter, Open-label, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HW211026 Ointment in Patients With Actinic Keratosis.
Not yet recruiting·HHubei Bio-Pharmaceutical Industrial Technological Institute Inc.·Phase 2·NCT07513454·80 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HW211026. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details